| Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ... Cell reports 19 (6), 1189-1201, 2017 | 1688 | 2017 |
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... Cancer discovery 7 (2), 188-201, 2017 | 1183 | 2017 |
| The biology of cancer testis antigens: putative function, regulation and therapeutic potential E Fratta, S Coral, A Covre, G Parisi, F Colizzi, R Danielli, HJM Nicolay, ... Molecular oncology 5 (2), 164-182, 2011 | 435 | 2011 |
| Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes JT Sockolosky, E Trotta, G Parisi, L Picton, LL Su, AC Le, A Chhabra, ... Science 359 (6379), 1037-1042, 2018 | 306 | 2018 |
| Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290 DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 246 | |
| Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells B Homet Moreno, JM Zaretsky, A Garcia-Diaz, J Tsoi, G Parisi, L Robert, ... Cancer immunology research 4 (10), 845-857, 2016 | 156 | 2016 |
| Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies L Sigalotti, A Covre, E Fratta, G Parisi, F Colizzi, A Rizzo, R Danielli, ... Journal of translational medicine 8, 1-22, 2010 | 124 | 2010 |
| Overcoming genetically based resistance mechanisms to PD-1 blockade DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ... Cancer discovery 10 (8), 1140-1157, 2020 | 113 | 2020 |
| Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ... Science translational medicine 12 (565), eabb0152, 2020 | 94 | 2020 |
| Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide S Coral, G Parisi, HJMG Nicolay, F Colizzi, R Danielli, E Fratta, A Covre, ... Cancer immunology, immunotherapy 62, 605-614, 2013 | 88 | 2013 |
| Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist G Parisi, JD Saco, FB Salazar, J Tsoi, P Krystofinski, C Puig-Saus, ... Nature communications 11 (1), 660, 2020 | 86 | 2020 |
| Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients L Sigalotti, E Fratta, E Bidoli, A Covre, G Parisi, F Colizzi, S Coral, ... Journal of translational medicine 9, 1-10, 2011 | 71 | 2011 |
| Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models A Covre, S Coral, H Nicolay, G Parisi, C Fazio, F Colizzi, E Fratta, ... Oncoimmunology 4 (8), e1019978, 2015 | 69 | 2015 |
| Anti–PD-1 therapy in melanoma BH Moreno, G Parisi, L Robert, A Ribas Seminars in oncology 42 (3), 466-473, 2015 | 64 | 2015 |
| Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients L Sigalotti, A Covre, E Fratta, G Parisi, P Sonego, F Colizzi, S Coral, ... Journal of translational medicine 10, 1-11, 2012 | 57 | 2012 |
| MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor S Caenepeel, K Cooke, S Wadsworth, G Huang, L Robert, BH Moreno, ... Oncotarget 8 (11), 17795, 2017 | 46 | 2017 |
| Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol. Res. 2016; 4: 845–857. doi: 10 … B Homet Moreno, JM Zaretsky, A Garcia-Diaz, J Tsoi, G Parisi, L Robert, ... CIR-16-0060, 0 | 45 | |
| Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications S Coral, A Covre, H Jmg Nicolay, G Parisi, A Rizzo, F Colizzi, ... British journal of cancer 107 (7), 1116-1124, 2012 | 26 | 2012 |
| Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? L Sigalotti, E Fratta, G Parisi, S Coral, M Maio British journal of cancer 105 (2), 327-328, 2011 | 23 | 2011 |
| IL-32γ potentiates tumor immunity in melanoma T Gruber, M Kremenovic, H Sadozai, N Rombini, L Baeriswyl, F Maibach, ... JCI insight 5 (18), 2020 | 22 | 2020 |
